Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial

NCT ID: NCT07183592

Last Updated: 2025-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

2830 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2028-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the intensive care unit, patients' care and secure drugs administration require a central venous catheter. These invasive devices can lead to complications, particularly infections. Most preventive recommendations focus on catheter insertion, line handling, and dressings. Few recommendations adress catheter dwell time, which is certainly the main source of infection. Part of the prevention strategy is the regular and systematic replacement of infusion sets , as they may become contaminated during use, mainly through the hands of healthcare professionals. Prolonged use increases the risk of infection. Infusion lines changes involve disconnecting the old sets, discarding infusion devices containing drug residues, and replacing them with new sterile devices.

Current international guidelines recommend replacing these sets every 4 days, and the Center for Disease Control and Prevention recommends not exceeding 7 days. Replacing these devices requires the time of qualified nurses, numerous sterile medical devices, and medications. In addition to the intended effect on infection prevention, the procedure has impacts on workload and costs.

The objective of the study is to demonstrate that changing infusion set every 7 days does not increase the rate of central venous catheters related infections compared with changing infusion set every 4 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care (ICU) Central Venous Catheter Related Infections Critical Care Nursing Catheter-associated Bloodstream Infections (CLABSI) Nursing Workload

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

7-day infusion set replacement

Infusion sets connected to the central venous catheter will be replaced every 7 days.

Group Type EXPERIMENTAL

7-day Infusion set replacement

Intervention Type PROCEDURE

7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.

4-day infusion set replacement

Infusion sets connected to the central venous catheter will be replaced every 4 days.

Group Type ACTIVE_COMPARATOR

4-day infusion set replacement

Intervention Type PROCEDURE

4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

7-day Infusion set replacement

7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.

Intervention Type PROCEDURE

4-day infusion set replacement

4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Any ICU patient with a central venous catheter (inserted by venipuncture) in place for less than 72 hours and with an expected dwell time of at least 7 days
* Patient affiliated with or covered by a social security system
* Patient who has given verbal consent or written consent from a third party or in the event that the patient is unable to give consent.

Exclusion Criteria

* Patient with a documented bloodstream infection at the time of inclusion
* Patient whose central venous catheter has been in place for more than 72 hours
* Patient with suspected catheter-related infection
* Patient whose study catheter was inserted using a guidewire exchange
* Patient previously enrolled in the study during the same ICU stay
* Patient whose condition, according to the clinician, does not allow safe placement of a central venous catheter, such as:

* Allergy to catheter material
* Confirmed deep vein thrombosis at the time of insertion
* Inflammatory skin disorder at the insertion site
* Patient admitted for extensive burns
* Inadequate understanding of the French language
* Pregnant, breastfeeding, or postpartum woman
* Person deprived of liberty by judicial or administrative decision
* Person receiving involuntary psychiatric care
* Person under legal guardianship or other legal protection measure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carole Haubertin

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

La Réunion University Hospital

Saint-Pierre, La Réunion, France

Site Status

Albi Hospital

Albi, , France

Site Status

Angers University Hospital

Angers, , France

Site Status

Belfort Hospital

Belfort, , France

Site Status

Bourges Hospital

Bourges, , France

Site Status

Caen University Hospital

Caen, , France

Site Status

Chartres Hospital

Chartres, , France

Site Status

Cholet Hospital

Cholet, , France

Site Status

Colombes Hospital

Colombes, , France

Site Status

Corbeil-Essonnes Hospital

Corbeil-Essonnes, , France

Site Status

AP-HP - Henri Mondor Hospital

Créteil, , France

Site Status

Dijon University Hospital

Dijon, , France

Site Status

Garches Hospital

Garches, , France

Site Status

Le Puy en Velay Hospital

Le Puy-en-Velay, , France

Site Status

Macon Hospital

Mâcon, , France

Site Status

Nantes University Hospital

Nantes, , France

Site Status

Orleans University Hospital

Orléans, , France

Site Status

AP-HP - Tenon Hospital

Paris, , France

Site Status

Pontoise Hospital

Pontoise, , France

Site Status

Strasbourg University Hospital

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carole Haubertin

Role: CONTACT

+332 41 35 40 82

Aurélie Hautefort

Role: CONTACT

+332 41 35 58 99

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nathalie Zemire

Role: primary

+33262359000

Simon Gayrard

Role: primary

+33563480653

Carole Haubertin

Role: primary

+332 41 35 40 82

Nahila Himer

Role: primary

+33384983573

Anna Bourreau

Role: primary

+33248484848

Agathe Hamelin

Role: primary

+33231064711

Justine Clavelou

Role: primary

+332 37 30 30 30

Charlotte Debarre

Role: primary

+332414966398

Blandine Dutrech

Role: primary

+33147606833

Justine Nunes

Role: primary

+33161695007

Marianne Le Joncour

Role: primary

+331 49 81 24 36

Jean-Pierre Quenot

Role: primary

+333 85 27 54 10

Segolene Jourdier

Role: primary

+33147107778

Isabelle Roure

Role: primary

+33471043537

Marine Alissant

Role: primary

+33380293685

Jerome Dauvergne

Role: primary

+332 40 16 52 84

Amandine Thiery

Role: primary

+332 38 51 44 46

Guillaume Voiriot

Role: primary

+331 56 01 55 98

Djeneba Camara

Role: primary

+33130755059

Julien Demiselle

Role: primary

+33369551079

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A01509-40

Identifier Type: OTHER

Identifier Source: secondary_id

49RC24_0290

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.